On Wednesday, Following U.S. Stocks were among the “Top Losers”: Gevo, (NASDAQ:GEVO), Nimble Storage, (NYSE:NMBL), Hemispherx Biopharma, (NYSEMKT:HEB), Ares Capital Corporation, (NASDAQ:ARCC)

Gevo, (NASDAQ:GEVO), with shares dwindled -3.59%, closed at $0.25.

Nimble Storage, (NYSE:NMBL), with shares declined -3.47%, settled at $23.66.

Hemispherx Biopharma, (NYSEMKT:HEB), with shares dipped -3.29%, and closed at $0.23.

Ares Capital Corporation, (NASDAQ:ARCC), dropped -3.33%, and closed at $16.82.

Latest NEWS regarding these Stocks are depicted underneath:

Gevo, Inc. (NASDAQ:GEVO)

Gevo, Inc. (GEVO), declared that the National Aeronautics and Space Administration (NASA) has purchased Gevo’s renewable Alcohol-to-Jet fuel (ATJ) for aviation use at the NASA Glenn Research Center in Cleveland, OH. Gevo’s ATJ is manufactured at its demonstration biorefinery located in Silsbee, TX, using renewable isobutanol produced at its Luverne, MN, isobutanol plant. The biorefinery, where Gevo also produces bio-paraxylene and bio-isooctane, is operated in conjunction with South Hampton Resources.

Since its founding, NASA has been dedicated to the advancement of aeronautics and space technologies. Over the past several years, NASA has been studying the effects of alternate biofuels on engine performance, emissions and aircraft-generated contrails at altitudes typically flown by commercial airliners. Results from recent tests showed that a blend of renewable jet fuel and standard jet fuel significantly reduced emissions, as contrast to using standard jet fuel alone, while not affecting flight operations.

“Gevo’s patented ATJ fuel is a true drop-in fuel, designed to be fully compliant with aviation fuel specifications and provide equal performance, counting fit-for-purpose properties and engine compatibility,” said Dr. Patrick Gruber, Gevo’s chief executive officer. “It is exciting to be working with NASA, a true leader in innovation worldwide.”

“Through testing initiatives, partners such as Lufthansa and the U.S. military are looking to certify our ATJ and accelerate its full-scale commercialization. ATJ from Gevo’s isobutanol is a clean burning, homegrown, drop-in jet fuel enabling a route to deliver aviation biofuels at scale and at a competitive cost,” Gruber added.

Gevo, Inc., a renewable chemicals and biofuels corporation, focuses primarily on the production and sale of isobutanol and related products from renewable feedstocks. Gevo’s strategy is to commercialize biobased alternatives to petroleum-based products to allow for the optimization of fermentation facilities’ assets, with the ultimate aim of maximizing cash flows from the operation of those assets.

Nimble Storage, Inc. (NYSE:NMBL)

Formerly on February 26, Nimble Storage, Inc. (NMBL), the flash storage solutions corporation, stated financial results for the fiscal fourth quarter 2015.

Fiscal Fourth Quarter 2015 Financial Highlights:

• Proceeds for the fourth quarter of fiscal 2015 were $68.3 million, contrast to $41.7 million in the fourth quarter of fiscal 2014, representing growth of 64% year-over-year.
• Non-GAAP Gross Margins of 67.2% for the fourth quarter of fiscal 2015, contrast to 67.2% in the fourth quarter of fiscal 2014.
• Non-GAAP Operating Margins of negative 12.4% for the fourth quarter of fiscal 2015, contrast to negative 20.9% in the fourth quarter of fiscal 2014.
• Adjusted EBITDA was negative $6.8 million or negative 10.0% of proceed contrast to negative 17.1% in the fourth quarter of fiscal 2014.
• GAAP net loss for the fiscal fourth quarter was $24.7 million, or $0.33 per basic and diluted share, contrast with a net loss of $13.2 million, or $0.29 per basic and diluted share in the fiscal fourth quarter of 2014.
• Non-GAAP net loss for the fiscal fourth quarter was $9.8 million, or $0.13 per basic and diluted share, contrast with a net loss of $9.1 million, or $0.14 per basic and diluted share in the fiscal fourth quarter of 2014.
• Foreign exchange loss was $1.1 million, which had a $0.01 per share negative influence on basic and diluted loss per share.

Nimble Storage, Inc. provides flash-optimized hybrid storage platform. The corporation’s software and storage systems handle various mainstream applications, counting virtual desktops, databases, email, collaboration, and analytics.

Hemispherx Biopharma, Inc. (NYSEMKT:HEB)

Hemispherx Biopharma, Inc. (HEB), stated that it has executed an contract with Emerge Health Pty Ltd. (“Emerge”) to seek approval of Ampligen, an experimental immunotherapeutic, for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate.

Hemispherx and Emerge will collaborate on seeking regulatory approval from Australia’s Therapeutic Goods Administration (“TGA”) and New Zealand’s Medicines and Medical Devices Safety Authority (“Medsafe”).

Under an exclusive license to sell, market, and distribute Ampligen in Australia and New Zealand to treat Chronic Fatigue Syndrome, Emerge will implement regulatory-compliant programs to educate physicians about Ampligen for CFS and seek orphan drug designation and approval of Ampligen to treat CFS. Hemispherx will support these efforts and will supply Ampligen at a predetermined transfer price.

Chris Rossidis, Co-Founder and COO of Emerge, said, “This contract with Hemispherx represents an opportunity which is exactly why Emerge was formed, to provide Australian and New Zealand patients with products that their physicians believe would be assistful. Given that there is no product approved specifically for the treatment of Chronic Fatigue Syndrome anywhere in the world, and at estimated prevalence rates of CFS in Australia and New Zealand, there could be 50,000 to 150,000 CFS patients with no dedicated treatment of this debilitating disease. We hope to be able to start providing Ampligen to the most severe of these patients during this year.”

Ampligen(R), an experimental therapeutic, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.

Emerge Health Pty Ltd is an innovative, specialized Australian pharmaceutical corporation focused on the marketing and sales of niche, high quality medicines to the hospital sector. Emerge Health is dedicated to providing exceptional products and support to ensure they meet their customers’ and partners’ needs and priorities.

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical corporation engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders especially life-threatening viruses.

Ares Capital Corporation (NASDAQ:ARCC)

Formerly on March 5, Ares Capital Corporation (ARCC), is providing additional details on its financing commitments closed during the fourth quarter of 2014, which were comprised of in Ares Capital’s earnings declaration released on February 26, 2015. Financing commitments made by Ares Capital in the fourth quarter totaled more than $1.3 billion.

Below are the eight of the transactions that closed during the fourth quarter.

1. Plantation Products / Freeman Spogli & Co.
2. Varsity Brands / Charlesbank Capital Partners
3. Global Franchise Group / Levine Leichtman Capital Partners
4. Stonewall Energy Center / Panda Power Funds & Siemens Financial Services
5. Triwater Holdings / Bolder Capital
6. The Alaska Club / Partnership Capital Growth Investors
7. Greenphire, Inc. / The Riverside Corporation
8. Zemax / Arlington Capital Partners

Ares Capital Corporation is a business development corporation specializing in attainment, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.